A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures

<table>Immunohistochemistry using uPA antibody.  Cytologically malignant cells stained positive for uPA cells from cytologic brushings obtained from a pancreatic adenocarcinoma patient during ERCP (arrows).</table>

HPB Surgery

fig1

Figure 1

Figure 1: A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures 

Figure 1 | A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures 